We have investigated whether hematopoietic stem cell transplantation (HSCT) before the death of children with cancer has a long-term effect on the physical and psychological well-being of the parents. A nationwide questionnaire was sent out to all bereaved parents in Sweden who had lost a child due to a malignancy from 1992 to 1997. Self-reported levels of anxiety, depression and quality of life as well as overall psychological and physical well-being in bereaved parents of children who underwent HSCT were compared with bereaved parents whose children did not receive a transplant. Bereaved parents whose children underwent HSCT had, according to a visual digital scale, an increased relative risk (RR) of long-term anxiety (RR 1.5; 95% confidence interval (CI) 1.0-2.1), poor psychological well-being (RR1.3; 95% CI 1.1-1.5), low quality of life (RR 1.4; 95% CI 1.2-1.7) and poor physical health (RR 1.3; 95% CI 1.1-1.5), whereas the State-Trait Anxiety Inventory and 'The Go¨teborg Quality of Life Instrument' were non-significantly increased (RR 1.3; 95% CI 0.8-2.3 and RR 1.7; 95% CI 0.9-3.3, respectively). The risks of these consequences were further augmented in case of multiple HSCT. We suggest that bereaved parents of children undergoing HSCT may be at greater risk of decreased psychological well-being than other bereaved parents of children with cancer.
Introduction
Hematopoietic stem cell transplant (HSCT) in children may be extremely stressful not only for the child, but also for the parents of that child. [1] [2] [3] In addition to interventions like radio-and chemo-therapy, some children must also endure HSCT, which entails repeated procedures, pain and isolation. It has previously been reported that the child's illness and treatment have an important role in the parents' lives for many years. 1 Similarly, it has been reported that a malignancy in a child affects the well-being of the parents negatively in the early phase of the disease. 4 Furthermore, we have previously reported an increased risk of anxiety and depression among bereaved parents compared with non-bereaved parents 4-6 years after the loss of a child with cancer. 5 Drew et al. 6 have reported results from an Australian single institution study of 56 bereaved parents of children treated for malignancies, 28 of whom had had a child treated with HSCT and 28 experienced no HSCT treatment. Increased anxiety, depression and stress were reported in parents whose child had undergone HSCT. A literature review on parental stress before, during and after pediatric HSCT revealed that the highest levels of parental stress were reported in the period preceding HSCT and during the acute phase and that stress levels decrease steadily after discharge in most parents, although stress levels still remained elevated post-HSCT in a subgroup of parents. 3 Very recently, Wolfe and colleagues reported on a large study comprising 141 children who died of cancer, and they concluded that HSCT is associated with significant suffering and less opportunity to prepare for end-of-life. 7 Larger samples and studies with longer follow-up may help us to understand whether bereaved parents of children treated with HSCT may be at a greater risk of psychological and physical morbidity than other bereaved parents in the long-term perspective. The aim of the present study was to assess the long-term psychological consequences in parents whose child had had a HSCT due to his or her malignancy before death.
Materials and methods

Participants
The national study reported here, including parents whose child died from a malignancy between the years 1992 and 1997 in Sweden, has been reported on earlier. 8, 9 In total, 97 parents reported that their child had undergone a HSCT and the responses of these parents are analyzed in the current study (for descriptive data on the participating parents, see Table 1 ). All children in this group were diagnosed with a malignancy before their 17th birthday and died before the age of 25. We identified the children through the Swedish National Register of Causes of Death linked to the Swedish National Register of Cancer. All diagnoses were verified by the child's former physician and/ or the medical records. The definition of being a parent was that the individual was registered as guardian of the child at the time of the child's diagnosis. Parents were eligible for the study if they were (1) born in any of the Nordic countries, (2) had a listed phone number and (3) spoke and understood Swedish. The Research Ethics Committee of the Karolinska Institutet, Stockholm, Sweden approved the study.
Method
Eligible parents were invited to participate by an introductory letter sent by post, in which the objectives of the study were briefly described. Ten days after this letter the parents were contacted by telephone and asked whether they would like to receive the questionnaire. If they agreed to participate, a questionnaire was sent to them and returned anonymously. The parents were contacted by telephone if the questionnaire had not been returned within another 10 days (this method has been described in more detail previously). 9 In the questionnaire parents were asked 'Did your child undergo a hematopoietic stem cell transplant?' to which the response alternatives were; 'No, he/she did not undergo a hematopoietic stem cell transplant, 'Yes, he/she had a hematopoietic stem cell transplant with his/her own bone marrow', 'Yes, he/she had a hematopoietic stem cell transplant with another person's bone marrow', 'Yes, he/ she had hematopoietic stem cell transplants y times'.
The outcome measure of this study was based on selfassessed psychological and physical health in the bereaved parents. The parents were asked to rate their psychological and physiological well-being over the last month at the time of the study, on a visual digital scale (VDS) that has previously been validated for anxiety and depression in larger samples. 10 The questionnaire assessed the symptoms of the parent's anxiety, depression, psychological wellbeing, physical health and self-assessed quality of life on the seven-point VDS using, for example, the following wordings: 'Have you been anxious during the past month?' (the scale was anchored with 'Never' to 'All the time'), 'How would you describe your quality of life the past month?' (the scale was anchored with 'Worst possible quality of life' to 'Best possible quality of life)'. 5 With regard to cutoff on the seven-point VDS, anxiety and depression were analyzed using the five most negative values (3-7/7) as affected by anxiety and depression, respectively. Similarly, for psychological well-being, physical health and quality of life the five most negative values (1-5/7) represent poor well-being, physical health and self-assessed quality of life. Anxiety and depression-related symptoms were also measured with 11, 12 We summarized the responses on the STAI-T and CES-D by giving a score on a scale of 1-4 (1 ¼ least severe symptoms, 4 ¼ most severe symptoms) for each answer and dividing the sum of these scores by the number of questions answered (all responses that had more than three missing values were excluded). For the summary average score on STAI-T and CES-D, we used a cutoff point at the 90th percentile among non-bereaved parents to define normal level of anxiety and depression. 5 To assess quality of life, in addition to the VDS, we also used 'The Go¨teborg Quality of Life Instrument', and we used a cut-off below the 10th percentile to define low quality of life. 13 Descriptive statistics were used and the results are presented as relative risk (RR) for the bereaved parents to express anxiety, depression, poor quality of life, poor psychological well-being or poor physical health in the group of parents who endured HSCT treatment of their child compared with parents whose child did not receive a HSCT. The data were also analyzed comparing parents whose child had an autologous HSCT with parents whose child had an allogeneic HSCT as well as parents whose child underwent multiple HSCTs with parents whose child underwent a single HSCT. When comparing categories, RRs were calculated as the ratio of the percentages, with a 95% confidence interval (95% CI).
Results
Descriptive data on the participating parents are presented in Table 1 . A total of 97 parents (22% of the responding parents) reported that their child had undergone a HSCT: 53 stated that their child had an autologous HSCT, 33 reported an allogeneic HSCT and 11 parents stated that their child had multiple HSCTs (4 only autologous and 1 only allogeneic; six no data). Leukemia was the most commonly reported diagnosis among the children who had undergone a HSCT (reported by 55 parents, 55% of the HSCT-group), whereas 13 parents reported sarcomas, 12 neuroblastomas, 8 lymphomas, 1 a brain tumor and 7 parents reported other diagnoses as indications for the HSCT (one no data).
Using VDS to measure anxiety, 31 out of 94 (33%) parents whose child underwent HSCT reported anxiety as compared with 74 out of 331 (22%) parents whose child did not. This represents a significant RR of 1.5 (95% CI 1.0-2.1) for anxiety among parents whose child had undergone a HSCT. The corresponding numbers when using STAI-T were 16 out of 96 (17%) and 41 out of 330 (12%), respectively (RR 1.3; 95% CI 0.8-2.3). Moreover, according to the VDS, anxiety was almost twice as prevalent in fathers of children who had experienced HSCT (RR 1.9; 95% CI 1.1-3.2) as compared with fathers whose child had not. No such increase in risk was found for fathers when using STAI-T and for mothers no such risk could be found by any of the scales. Using the VDS for self-assessed psychological well-being, 60 out of 93 (65%) parents whose child had received a HSCT reported poor psychological well-being compared with 169 out of 333 (51%) parents with children that did not undergo HSCT (RR 1.3; 95% CI 1.1-1.5; Table 2 ).
Self-assessed quality of life and physical health were, according to the VDS instrument, significantly worse in the group of parents whose child had a HSCT as compared with parents whose child had not (RR 1.4; 95% CI 1.2-1.7 and RR 1.3; 95% CI 1.1-1.5), respectively). Using the Go¨teborg QoL scale to assess quality of life, the corresponding RR was 1.7; 95% CI 0.9-3.3. Regarding the parents' quality-of-life, both mothers and fathers whose child had experienced HSCT had statistically significant reduced quality-of-life scores compared with the other parents (RR for mothers 1.3; 95% CI 1.0-1.7) and RR for fathers 1.5; 95% CI 1.1-2.0) according to the VDS, but no Table 2 Self-assessed morbidity in bereaved parents whose child had a HSCT vs parents whose child did not have a HSCT (no./total no. (%)) 15 significant differences were found when using the Go¨teborg QoL scale (RR 2.3; 95% CI 1.0-5.3 and RR 1.2; 95% CI 0.4-3.5, respectively). Depression did not differ significantly between the parents whose child had a HSCT or not by either the VDS or the CES-D, whereas poor psychological well-being and poor physical health, both studied with the VDS, were more often reported by the mothers (Table 2) . At 4-6 years after bereavement but not 7-9 years after bereavement, anxiety (RR 1.6; 95% CI 1.1-2.6), poor psychological well-being (RR 1.5; 95% CI 1.2-1.9) and low quality of life (RR 1.5; 95% CI 1.2-1.9) were more prevalent according to the VDS in parents whose child had received a HSCT compared with parents whose child had not, whereas the STAI-T for anxiety and the Go¨teborg QoL instrument revealed no significant such risks at any of these time periods. At 7-9 years after bereavement parents with the experience of a HSCT in their child reported poorer physical health (RR 1.4; 95% CI 1.1-1.7) as compared with parents without such an experience (Table 3) . When comparing parents whose child underwent allogeneic vs autologous transplants, there was, according to the VDS instrument, an increased risk of poor physical health (RR 1.4; 95% CI 1.1-1.8) in parents whose child had an allogeneic HSCT compared with parents whose child had an autologous HSCT. For fathers there was also a statistically significant increased risk of low quality of life (RR 1.7; 95% CI 1.0-2.7) if the child had undergone an allogeneic HSCT compared with an autologous HSCT, but none of these risks were found using the Go¨teborg QoL scale (Table 4) .
With regard to multiple HSCTs, 11 parents stated that their child went through multiple HSCTs and, according to the VDS instrument, in this group the risks of anxiety, depression, poor psychological well-being, low quality of life and poor physical health were all statistically significantly increased as compared with parents whose child underwent a single HSCT. The CES-D and Go¨teborg QoL instruments indicated similar trends for depression and quality of life, but the findings were not statistically Table 3 Self-assessed morbidity in bereaved parents whose child had a HSCT vs parents whose child did not have a HSCT (no./total no. (%)) Anxiety assessed by STAI-T showed even greater risks for mothers and fathers together (RR 3.5; 95% CI 1.5-8.2) and for fathers alone (RR 7.0; 95% CI 1.9-25.6) than did the VDS instrument (Table 5) .
Discussion
This study suggests that parents who lost their child to cancer 4-9 years earlier may be at increased risk of longterm self-assessed anxiety and poor psychological wellbeing, as well as reduced quality of life and physical health if their child underwent a HSCT before death, as compared with parents whose child with cancer died without having had a HSCT. With regard to time after bereavement, parents studied 4-6 years after bereavement showed increased risk of long-term self-assessed anxiety, poor psychological well-being and reduced quality of life, whereas no such risks were identified in parents studied 7-9 years after bereavement ( Table 3 ). The risk of poor physical health increased further for parents whose child underwent an allogeneic HSCT and for those whose child had multiple HSCTs. For the latter group we could also see an increased risk of depression and poor physical health (Tables 4 and 5) . Anxiety evaluated by the STAI-T instrument showed a similar trend as with the VDS, with increased long-term Table 4 Self-assessed morbidity in bereaved parents whose child had an allogeneic HSCT vs parents whose child had an autologous HSCT (no./total no. (%)) self-assessed anxiety among parents who lost their child after a HSCT as compared with parents whose child with cancer died without having had a HSCT, but these findings were NS (Table 2) , whereas the increased risk of anxiety for parents whose child underwent multiple HSCTs was significant also with this instrument (Table 5) . Similarly, the Go¨teborg QoL instrument also revealed a NS trend toward lower quality of life among parents who lost their child after a HSCT as well as among parents whose child underwent multiple HSCTs. To conclude, with the VDS instrument there are more significant differences between the HSCT and non-HSCT groups, and the rates of psychological morbidity are quite high, whereas with the STAI-T, CES-D and Go¨teborg QoL instruments we often find similar trends, but these findings are most often NS. Our VDS data indicating increased risk of self-assessed anxiety, low quality of life, poor physical health and poor psychological well-being in the group of parents whose children had been transplanted are, in general, in agreement with those of Drew and co-workers, who found increased anxiety, depression and stress in the parents to children who were transplanted. 6 Although they found depression to be more prevalent in parents whose child had been transplanted, we noted a similar trend in our material but this was not statistically significant. We cannot specifically explain why remaining anxiety but not depression was more frequent in parents whose children had been transplanted, but in a previous report on 449 bereaved parents to children with cancer, we also found a trend to somewhat higher risk of anxiety (RR 1.5) than depression (RR 1.4), in bereaved parents compared with the nonbereaved group. 5 One explanation for the higher risk of late psychological morbidity could be that parents may have encountered higher levels of traumatic stress at the time of the HSCT treatment, as compared with parents of children who were not transplanted. As HSCT in children with cancer often is used after one or multiple relapses, the parents may find HSCT as the final and only remaining possibility for survival of their child. Moreover, the stress could be further augmented by the early treatment consequences, including prolonged cytopenia and associated infections, which may be perceived as traumatic by the parents. Therefore, it is possible that when the hope of cure that the HSCT treatment might bring is ultimately lost (we study parents of children who have died), the stress level may be particularly high. Stressor severity has been consistently shown to be an important predictor of post-traumatic stress disorder (PTSD) in other trauma survivor groups. In line with this, Pelcovitz et al. 15 reported that 38% of mothers meeting lifetime PTSD criteria had children with a severe level of illness as compared with 25% of mothers not meeting lifetime PTSD criteria.
14 Notably, the estimated levels of post-traumatic stress are often even higher in parents of children with cancer than in pediatric or adult cancer patients themselves, 14 and it has been reported that a sub-group of parents experience distress related to the child's cancer several years after the diagnosis. 4 According to the VDS instrument, psychological morbidity in bereaved parents due to the exposure to the child's HSCT seems to be higher during the period 4-6 years following bereavement as compared with the period 7-9 years since bereavement, following the same timeline as the overall risk of anxiety and depression in parents who lost a child to cancer. 5 Regarding these data on the two different time periods, the STAI-T and Go¨teborg QoL instruments did not show similar trends as the VDS. In the study by Drew and co-workers, based on a 4-year mean-time of follow-up, the relationship between psychological morbidity and time since bereavement was not explored. 6 In addition to the increased psychological morbidity in bereaved parents whose child underwent HSCT, we also found the parents' quality of life to be affected as compared with bereaved parents whose child did not undergo HSCT. To our knowledge, no previous study has reported on bereaved parents' long-term quality of life following their child's treatment by HSCT. Notably, Manne et al. 16 studied 111 non-bereaved mothers to children who underwent HSCT and found a low quality of life both at the time of HSCT and 18 months later. Close to 20% of the mothers, particularly younger mothers, exhibited clinical distress reactions such as anxiety and depression at the time of the child's transplantation.
There have previously been several studies on parental distress during HSCT treatment. Streisand et al. 17 presented a study on stress levels in 22 mothers of children undergoing HSCT over the course of hospitalization and found stress levels to be at their highest before admission. Interestingly, they found that the mothers expressed less perceived stress than a control group. They hypothesize that admission may represent a relief in the primary burden of care that may be shifted from the parents to the hospital staff. They also emphasize the importance of further documentation of parental stress levels both during HSCT and long-term. Gardner et al. 18 reported similar findings, with parental experiences of guilt before the transplantation, reaching a maximum during the pretransplant immunosuppression. Gardner et al. also reported increased parental anxiety when the child was discharged from the hospital unit.
Complementary to these studies there are also reports of parental distress throughout the course of the treatment. 19, 20 In 2005 Phipps et al. 21 presented data on parents of 151 children undergoing HSCT, studied upon admission and monthly throughout a 6 months period. They reported that there are identifiable predictors of parental distress, such as previous parent and patient illness-related distress, premorbid child internalization behavior problems and parental avoidance of coping, and they suggest that if these predictors can be identified at an early stage one may identify parents who are in need of intervention.
An early publication on psychological and emotional problems in conjunction with the child's HSCT by Gardner et al. 18 focused on the experience of seven children and their families concerning straightforward communication as a part of the management. Presumably, parents whose child is being treated with HSCT are likely to be aware of the child's possible death and may talk about death with their child. In another study, Forinder et al. 1 showed that parents of children undergoing HSCT express both concern for the children and a wish for more information about their children's illness from a long-term perspective, as well as general improvement in communication. The data was collected through interviews with the parents of 20 children during 4-8 years after HSCT, and a second interview 4 years later. The parents expressed a need for more information and more opportunities to discuss existential issues. When parents felt that they participated in the care of the child they were seen to cope better with the treatment and the side effects. The child's illness and treatment had a strong influence on the everyday lives of all the parents. 1 In parents whose child had an allogeneic HSCT compared with parents whose child had an autologous HSCT, the VDS data indicated an increased risk of poor physical health as well as, for fathers, an increased risk of low quality of life but the latter findings were not supported by the Go¨teborg QoL instrument (Table 4) . We did not specifically ask the parents whose child had an allogeneic HSCT on what donor that was used. Therefore, based on the current data we cannot tell whether the aggravated problems after allogeneic HSCT for the parents were due primarily to the use of sibling and other family donors, or if the problems rather could be explained by the extended procedures and stress associated with allogeneic HSCT itself, including searching and waiting for a sufficiently matched donor.
One limitation of this study is the discrepancy between the VDS data and the data provided by the STAI-T, CES-D and Go¨teborg QoL instruments. In general, the VDS and the other instruments show similar trends, but significant differences are more often found in the data provided by the VDS. Of note, in our face-to-face validation of the questionnaire the parents understood each question well when using the VDS, whereas it was harder for them to understand the questions included in the STAI-T, CES-D and Go¨teborg QoL instruments. Another limitation of this study is the lack of information on when the child underwent the HSCT and whether it was close to the child's death or earlier on in the treatment. Moreover, a number of years have passed since the affected children died, hence the care and support offered to parents may have changed. Our study is a cross-sectional study and not a longitudinal study. It has the strength of being both nationwide and population-based, and it also has a high participation rate (80%). To our knowledge, there is as yet no other study with these strict inclusion criteria and, moreover, we have also been able to present data on fathers, mothers, autologous HSCT, allogeneic HSCT and multiple HSCTs separately. Finally, it may also be of value that the parents filled out the questionnaire at home without any input from the investigators and that they all have been able to remain anonymous.
Losing a child will always remain a traumatic experience and having one's child treated with HSCT increases the risk of psychological and physical morbidity in bereaved parents even further. It would be valuable to identify potential risk factors that may be modifiable or avoidable in the care of children undergoing HSCT, with the aim not only to decrease the risk of psychological and physiological morbidity in bereaved parents, but most importantly to improve the care of the seriously ill child. Health care professionals may arrange for parents whose child is going to have a HSCT to see a social worker to prepare for the stress the HSCT elicits. This may be of even greater importance when the child's second HSCT is planned.
